Skye Bioscience, Inc.

To unlock the pharmaceutical potential of cannabinoids to treat diseases with significant unmet needs for patients around the world.

Recent News

  • Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference

    San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announced today that it will present a corporate overview at the RHK 2022 Disruptive Growth Conference being held December 5-6, 2022, at the offices of Reed Smith in New York City.Punit Dhillon, Chief Executive Officer and Chair, will present on Monday, December 5th at 2:00 PM ET. The presentation will...

    2022-11-22 7:00 AM EST
  • Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA

    San Diego, California--(Newsfile Corp. - November 17, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives, has submitted an Investigational New Drug application ("IND") to the U.S. Food and Drug Administration for SBI-100 Ophthalmic Emulsion ("SBI-100 OE), which it is developing for the treatment of glaucoma. Once opened, the IND will allow the Company to conduct clinical trials in the United States.SBI-100 OE is a novel synthetic molecule targeting the...

    2022-11-17 7:00 AM EST
  • Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for SBI-100

    - Recruitment for cohort 1 has begun- Clinical trial material manufactured and shipped to AustraliaSan Diego, California--(Newsfile Corp. - November 16, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion ("SBI-100 OE"). As previously announced, this study has received...

    2022-11-16 7:00 AM EST
  • Skye Bioscience Closes Acquisition of Emerald Health Therapeutics

    San Diego, California--(Newsfile Corp. - November 10, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has concluded the merger transaction with Emerald Health Therapeutics ("Emerald"). Both companies' shareholders voted in favor of the transaction and the Supreme Court of British Columbia approved the transaction. On November 7, 2022, Skye and Emerald waived the condition that Skye obtain a conditional approval to list its shares on...

    2022-11-10 10:48 PM EST
  • Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.

    San Diego, California--(Newsfile Corp. - September 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs, reports that its stockholders voted in favor of all proposals presented at its special meeting held today, including the proposal to approve the proposed acquisition (the "Arrangement") of Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("EHT") by Skye. A total of 74% of shares...

    2022-09-30 3:24 PM EDT
  • Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion

    San Diego, California--(Newsfile Corp. - June 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has received regulatory approval to begin its first-in-human Phase 1 clinical study of SBI-100 Ophthalmic Emulsion ("SBI-100 OE") from the Australian Human Research Ethics Committee ("HREC"). SBI-100 OE is a patented drug representing a new class of therapeutics to potentially treat glaucoma.The primary endpoints for this randomized, double-masked, placebo-controlled Phase...

    2022-06-30 7:00 AM EDT